KIF13A Protein

KIF13A Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">KIF13A Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Residues</td>
</tr>
<tr>
<td class="label">Motor domain (Neck region)</td>
<td>1-350</td>
</tr>
<tr>
<td class="label">Coiled-coil region</td>
<td>350-500</td>
</tr>
<tr>
<td class="label">Tail domain</td>
<td>500-1780</td>
</tr>
<tr>
<td class="label">PH-like domain</td>
<td>1600-1780</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">KIF13A activators</td>
<td>Enhance APP non-amyloidogenic processing</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Restore KIF13A expression</td>
</tr>
<tr>
<td class="label">Small molecule modulators</td>
<td>Enhance motor activity</td>
</tr>
<tr>
<td class="label">Microtubule-stabilizing agents</td>
<td>Improve axonal transport</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">APP</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">MINT1/X11</td>
<td>Cargo adapter</td>
</tr>
<tr>
<td class="label">Rab5</td>
<td>Endosomal recruitment</td>
</tr>
<tr>
<td class="label">Rab11</td>
<td>Recycling endosome</td>
</tr>
<tr>
<td class="label">AP-2</td>
<td>Clathrin adaptor</td>
</tr>
<tr>
<td class="label">Dynamin</td>
<td>V

KIF13A Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">KIF13A Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Residues</td>
</tr>
<tr>
<td class="label">Motor domain (Neck region)</td>
<td>1-350</td>
</tr>
<tr>
<td class="label">Coiled-coil region</td>
<td>350-500</td>
</tr>
<tr>
<td class="label">Tail domain</td>
<td>500-1780</td>
</tr>
<tr>
<td class="label">PH-like domain</td>
<td>1600-1780</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">KIF13A activators</td>
<td>Enhance APP non-amyloidogenic processing</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Restore KIF13A expression</td>
</tr>
<tr>
<td class="label">Small molecule modulators</td>
<td>Enhance motor activity</td>
</tr>
<tr>
<td class="label">Microtubule-stabilizing agents</td>
<td>Improve axonal transport</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">APP</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">MINT1/X11</td>
<td>Cargo adapter</td>
</tr>
<tr>
<td class="label">Rab5</td>
<td>Endosomal recruitment</td>
</tr>
<tr>
<td class="label">Rab11</td>
<td>Recycling endosome</td>
</tr>
<tr>
<td class="label">AP-2</td>
<td>Clathrin adaptor</td>
</tr>
<tr>
<td class="label">Dynamin</td>
<td>Vesicle scission</td>
</tr>
<tr>
<td class="label">Clathrin</td>
<td>Coat component</td>
</tr>
<tr>
<td class="label">SNX2</td>
<td>Sorting nexin</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Application</td>
</tr>
<tr>
<td class="label">KIF13A knockout mice</td>
<td>AD pathology studies</td>
</tr>
<tr>
<td class="label">KIF13A knockdown in dopamine neurons</td>
<td>PD models</td>
</tr>
<tr>
<td class="label">Primary neuron cultures</td>
<td>Live imaging</td>
</tr>
<tr>
<td class="label">Patient-derived iPSCs</td>
<td>HSP mutations</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>KIF13A Involvement</td>
</tr>
<tr>
<td class="label">Alzheimer's</td>
<td>APP trafficking, AMPAR transport</td>
</tr>
<tr>
<td class="label">Parkinson's</td>
<td>α-synuclein endosomal sorting</td>
</tr>
<tr>
<td class="label">HSP</td>
<td>Direct mutation causality</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Axonal transport defects</td>
</tr>
<tr>
<td class="label">FTD</td>
<td>Autophagy, protein clearance</td>
</tr>
<tr>
<td class="label">CMT2</td>
<td>Peripheral axon transport</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">15 edges</a></td>
</tr>
</table>

KIF13A (Kinesin-3 Family Member 13A) is a 189 kDa monomeric kinesin motor protein that functions as a key regulator of endocytic trafficking, synaptic vesicle transport, and protein sorting in neurons. As a member of the kinesin-3 family (KIF1 family), KIF13A plays critical roles in neuronal development, synaptic plasticity, and the regulation of amyloid precursor protein (APP) processing—making it a protein of significant interest in neurodegenerative disease research. [@kikuchi2020][@takuchi2021]

Protein Structure

KIF13A possesses a distinctive domain architecture adapted for its specialized transport functions in neurons:

The motor domain contains the conserved kinesin catalytic core with microtubule-binding activity. Unlike conventional kinesins that form dimers, KIF13A functions as a monomer with high processivity, allowing efficient transport over long axonal distances. The PH-like (Pleckstrin Homology) domain at the C-terminus enables direct binding to phosphoinositides on endosomal membranes, targeting KIF13A to specific cellular compartments. [@kikkawa2019]

Structural Features

• Monomeric motor — Unlike most kinesins, KIF13A functions as a monomer, achieving high processivity through unique mechanical properties
• PH domain — Enables direct membrane association without additional adaptors
• Cargo-binding tail — Contains multiple protein interaction motifs for diverse cargo recognition

Normal Neuronal Function

Synaptic Vesicle Transport

KIF13A is highly enriched in axons and dendrites where it mediates the transport of synaptic vesicle precursors, endocytic vesicles, and signaling endosomes. In dendritic spines, KIF13A localizes to postsynaptic compartments where it regulates the trafficking of AMPA receptors (AMPARs), influencing synaptic plasticity and glutamatergic signaling. Studies demonstrate that KIF13A knockdown significantly reduces AMPAR surface expression, impairing long-term potentiation (LTP). [@guo2019]

Endocytic Trafficking

KIF13A plays a central role in clathrin-mediated endocytosis and subsequent endosomal sorting. The protein localizes to early endosomes and recycling endosomes, directing cargo trafficking between the plasma membrane, endosomes, and the trans-Golgi network. This function is essential for neuronal membrane protein turnover and signaling receptor regulation. [@chao2019]

Axonal Development

During neuronal development, KIF13A contributes to axonal outgrowth and guidance. The motor protein transports growth cone vesicles containing guidance receptors and adhesion molecules, enabling proper neuronal polarity establishment and circuit formation. Loss of KIF13A function results in guidance defects and abnormal axonal branching. [@okada2015][@niwa2016]

APP Processing and Trafficking

A critical function of KIF13A in neurons is its role in amyloid precursor protein (APP) trafficking. KIF13A directly interacts with APP and directs its transport through the endocytic pathway. This trafficking is crucial for determining whether APP undergoes amyloidogenic (β-secretase cleavage) or non-amyloidogenic (α-secretase cleavage) processing. Proper KIF13A function helps maintain the balance toward non-amyloidogenic processing, reducing amyloid-beta (Aβ) generation. [@kikuchi2020]

Role in Alzheimer's Disease

Amyloid Processing Dysregulation

In Alzheimer's disease (AD), KIF13A function becomes dysregulated, contributing to altered APP trafficking and increased amyloidogenic processing. Reduced KIF13A expression or activity leads to impaired APP transport, resulting in enhanced β-secretase (BACE1) cleavage and elevated Aβ production. Conversely, KIF13A overexpression promotes non-amyloidogenic APP processing by enhancing α-secretase cleavage, suggesting KIF13A as a potential therapeutic target. [@kikuchi2020]

Synaptic Dysfunction

KIF13A deficiency contributes to synaptic failure in AD through multiple mechanisms:

Evidence from Research

Studies in AD mouse models demonstrate:

• Reduced KIF13A expression in hippocampal neurons
• Impaired APP retrograde transport
• Accumulation of APP in early endosomes
• Enhanced BACE1 cleavage of APP

Therapeutic Implications

KIF13A represents an attractive target for AD therapeutic development:

Role in Parkinson's Disease

Dopaminergic Neuron Vulnerability

KIF13A dysfunction contributes to Parkinson's disease (PD) pathogenesis through impaired trafficking in dopaminergic neurons. Studies in PD models demonstrate that KIF13A expression is reduced in the substantia nigra, leading to:

• Accumulation of α-synuclein in endosomes
• Impaired dopamine receptor recycling
• Dysregulated iron metabolism via transferrin trafficking
• Mitochondrial quality control defects

Autophagy-Lysosome Pathway

KIF13A plays a role in autophagy initiation by transporting autophagy-related vesicles. In PD, impaired KIF13A function contributes to the accumulation of dysfunctional autophagosomes and reduced clearance of α-synuclein aggregates.

α-Synuclein Interconnection

The intersection between KIF13A dysfunction and α-synuclein pathology in PD involves:

Role in Other Neurological Disorders

Hereditary Spastic Paraplegia (HSP)

KIF13A mutations cause a subset of hereditary spastic paraplegia (HSP), characterized by progressive lower limb spasticity. These mutations typically affect the motor domain, impairing microtubule binding and motility. The disease mechanism involves impaired axonal transport in corticospinal tract neurons. [@matsuda2023]

Charcot-Marie-Tooth Disease

KIF13A variants have been implicated in Charcot-Marie-Tooth disease type 2 (CMT2), a hereditary peripheral neuropathy. Mutations disrupt axonal transport in peripheral neurons, leading to progressive muscle weakness and sensory loss.

Protein Interactions

Signaling Pathways

KIF13A activity is regulated by several neuronal signaling pathways:

• PI3K/Akt pathway — Phosphorylation enhances motor activity
• CaMKII — Regulates cargo binding and localization
• GSK-3β — Modulates microtubule interaction
• LKB1-AMPK — Energy-sensing regulation of transport
• PKC — Modulates endosomal trafficking

KIF13A-Mediated Transport Pathway

Therapeutic Targeting Strategies

Small Molecule Activators

Small molecules that enhance KIF13A motor activity or expression are being explored as AD therapeutics. These compounds would potentially:

• Promote non-amyloidogenic APP processing
• Improve synaptic vesicle cycling
• Enhance endosomal trafficking
• Restore dendritic spine density

Gene Therapy Approaches

Viral vector-mediated KIF13A expression restoration represents a direct therapeutic strategy, particularly for KIF13A haploinsufficiency disorders:

• AAV9-mediated KIF13A delivery
• Promoter selection for neuron-specific expression
• Dose optimization for safety and efficacy

Microtubule-Stabilizing Agents

Drugs that stabilize microtubules (e.g., taxanes, epothilones) can enhance KIF13A-mediated transport by improving microtubule tracks, though these approaches face significant blood-brain barrier penetration challenges. Research into BBB-penetrant microtubule stabilizers is ongoing.

Research Models

Future Research Directions

Biomarker Potential

KIF13A expression levels in cerebrospinal fluid (CSF) and blood may serve as a biomarker for:

• Axonal transport dysfunction in early AD/PD
• Disease progression monitoring
• Therapeutic response assessment

KIF13A in Glia

While primarily studied in neurons, KIF13A also functions in glial cells:

• Astrocytes: Regulates glutamate transporter trafficking
• Microglia: Controls endosomal trafficking in immune response
• Oligodendrocytes: Myelin protein transport

Intersection with Other Pathologies

KIF13A dysfunction intersects with multiple neurodegenerative hallmarks:

Clinical Implications

Understanding KIF13A biology informs multiple therapeutic strategies:

• Early intervention — KIF13A enhancement before major axonal loss
• Disease-modifying approaches — Targeting core transport dysfunction
• Combination therapies — Synergy with amyloid/tau/α-syn targeting
• Personalized medicine — KIF13A genetic variants predict treatment response

Cross-Disease Relevance

KIF13A dysfunction appears in multiple neurodegenerative conditions:

This broad relevance makes KIF13A a high-value target for pan-neurodegeneration research.

Summary

KIF13A is a critical neuronal motor protein linking endocytic trafficking, synaptic function, and neurodegeneration. Its role in APP processing positions it as a key node in Alzheimer's disease pathogenesis, while its functions in dopaminergic neurons and autophagy make it relevant for Parkinson's disease. Therapeutic targeting of KIF13A represents a promising but challenging approach, requiring careful consideration of motor function, cargo specificity, and cellular context.

The ongoing research into KIF13A's molecular mechanisms, disease interactions, and therapeutic potential continues to expand our understanding of axonal transport in neurodegeneration and may yield novel treatment strategies for these devastating diseases.

Cross-Links

• [KIF13A Gene](/genes/kif13a) — Gene page
• [Kinesin-3 Family](/proteins/kinesin-3-protein) — Related proteins
• [APP Protein](/entities/app-protein) — APP processing
• [Axonal Transport](/mechanisms/axonal-transport) — Transport mechanisms
• [Synaptic Vesicle Cycle](cell-types/synaptic-vesicle-cycle) — Synaptic function
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease context
• [Parkinson's Disease](/diseases/parkinsons-disease) — Disease context

References